BioSpace News Archive

Transparency Market Research has published a new report titled, “Minimally Invasive Surgery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

Inflazome, the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, announces the successful completion of a Phase I study of Inzomelid, alongside positive results from a Cryopyrin-Associated Periodic Syndrome patient dosed with Inzomelid.

Oncopeptides AB announces the final topline results from the pivotal phase 2 HORIZON study evaluating melflufen in relapsed refractory multiple myeloma patients.

AgNovos Healthcare announced that its newest investigational product, AGN1 Local Osteo-enhancement Procedure Small Volume Kit, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration.

Xellia Pharmaceuticals, a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has received approval from the US Food and Drug Administration allowing the Company to commence manufacturing of drug products at its Cleveland, Ohio site.

Lonza has launched a new medium to enhance and accelerate the production of Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect cells

Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic. Clinical and immune activity of Bria-IMT™, alone or in combination with checkpoint inhibitors, KEYTRUDA ® and INCMGA00012, in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting, postponed to August 2020. BERKELEY, Calif. and VA

Aviptadil is a patented synthetic form of Vasoactive Intestinal Polypeptide that has previously shown promise in treating ARDS - Coronavirus (COVID-19) death is primarily caused by Acute Respiratory Distress Syndrome (ARDS), in which severe inflammation causes the lungs to fill with fluid and even mechanical ventilation is unable to maintain life. The syndrome is caused by a Cytokine Storm unleashed by viral particles. - VIP is known to have potent anti-cytokine effects in nu

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announces that it will explore the role of an inflammatory cytokine, LIGHT, in patients with COVID-19 induced Acute Respiratory Distress. The Company will use its proprietary free LIGHT assay as well as a multiplex assay to determine whether there are differences

BiomX Inc . today reported financial results and provided a business update for the full year ended December 31, 2019.